FLT3 and hematopoietic and lymphoid cell neoplasm: Interestingly, in an independent study in hematopoietic cancer, the combination of JQ1 affecting the c-Myc levels and a FLT3 tyrosine kinase inhibitor (TKI) was synergistic in overcoming resistance to the FLT3 TKI in acute myeloid leukemia (AML) cells (Fiskus et al., 2014).